Search

Your search keyword '"Newhall, Kathryn J."' showing total 7 results
Start Over Author "Newhall, Kathryn J." Journal blood
7 results on '"Newhall, Kathryn J."'

2. Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Author

Abramson, Jeremy S., Ramakrishnan, Aravind, Pierola, Ana Alfonso, Braunschweig, Ira, Cartron, Guillaume, Thieblemont, Catherine, Pérez-Simón, Jose A., Barba, Pere, Riedell, Peter A., Solano, Carlos, Gastinne, Thomas, LaCroce, Alexandra, Thomas, Denise, Poirot, Camille, Meadows, Sarah, Newhall, Kathryn J., Lee, Daniel J., Frattini, Mark G., and Bachy, Emmanuel

Published
2023
Full Text
View/download PDF

3. Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., and Boissel, Nicolas

Published
2023
Full Text
View/download PDF

4. Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Author

Krupka, Christina, primary, Brauneck, Franziska, additional, Lichtenegger, Felix S, additional, Kufer, Peter, additional, Kischel, Roman, additional, Zugmaier, Gerhard, additional, Köhnke, Thomas, additional, Altmann, Torben, additional, Schneider, Stephanie, additional, Fiegl, Michael, additional, Spiekermann, Karsten, additional, Sinclair, Angus M, additional, Newhall, Kathryn J, additional, Frankel, Stanley R, additional, Baeuerle, Patrick, additional, Hiddemann, Wolfgang, additional, Riethmüller, Gert, additional, and Subklewe, Marion, additional

Published
2014
Full Text
View/download PDF

6. PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Author

Krupka, Christina, primary, Kufer, Peter, additional, Kischel, Roman, additional, Zugmaier, Gerhard, additional, Köhnke, Thomas, additional, Lichtenegger, Felix S, additional, Schnorfeil, Frauke M, additional, Altmann, Torben, additional, Schneider, Stephanie, additional, Fiegl, Michael, additional, Spiekermann, Karsten, additional, Sinclair, Angus M, additional, Newhall, Kathryn J, additional, Frankel, Stanley R, additional, Baeuerle, Patrick, additional, Hiddemann, Wolfgang, additional, Riethmüller, Gert, additional, and Subklewe, Marion, additional

Published
2014
Full Text
View/download PDF

7. Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivoand CD33 Upregulation on AML Cells

Author

Krupka, Christina, Brauneck, Franziska, Lichtenegger, Felix S, Kufer, Peter, Kischel, Roman, Zugmaier, Gerhard, Köhnke, Thomas, Altmann, Torben, Schneider, Stephanie, Fiegl, Michael, Spiekermann, Karsten, Sinclair, Angus M, Newhall, Kathryn J, Frankel, Stanley R, Baeuerle, Patrick, Hiddemann, Wolfgang, Riethmüller, Gert, and Subklewe, Marion

Abstract

Bispecific T-cell engager (BiTE®) antibodies represent a promising tool for anti-leukemic immunotherapy. The CD19/CD3-bispecific antibody blinatumomab was shown to be active in refractory and relapse patients with B-precursor acute lymphoblastic leukemia (Topp et al, ASCO 2014). Transient, blinatumomab-mediated cytokine release syndrome has been linked to target cell numbers as this phenomenon is predominantly observed within the first treatment cycle. In our previous work, we demonstrated that the bispecific CD33/CD3 BiTE® antibody AMG 330 is able to induce activation and proliferation of residual autologous T-cells and effectively mediates lysis of primary acute myeloid leukemia (AML) cells (Krupka et al, Blood 2014; 123(3):356-65).

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results